• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.

作者信息

Guo F, Li J, Zhang S, Du W, Amarachintha S, Sipple J, Phelan J, Grimes H L, Zheng Y, Pang Q

机构信息

Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

出版信息

Leukemia. 2014 Jan;28(1):203-6. doi: 10.1038/leu.2013.215. Epub 2013 Jul 15.

DOI:10.1038/leu.2013.215
PMID:23852546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3947286/
Abstract
摘要

相似文献

1
mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.mTOR激酶抑制剂通过抑制FANCD2表达使T细胞淋巴母细胞白血病对化疗诱导的DNA损伤敏感。
Leukemia. 2014 Jan;28(1):203-6. doi: 10.1038/leu.2013.215. Epub 2013 Jul 15.
2
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.mTOR 通路调控 FANCD2 表达促进肿瘤细胞抵抗 DNA 双链断裂。
Cancer Res. 2013 Jun 1;73(11):3393-401. doi: 10.1158/0008-5472.CAN-12-4282. Epub 2013 Apr 30.
3
Clinical Significance of Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.基因表达在肝细胞癌中的临床意义及其与肿瘤进展的关联
Anticancer Res. 2017 Mar;37(3):1083-1090. doi: 10.21873/anticanres.11420.
4
Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.鉴定山金车二醇 C 作为一种新型化疗增敏剂，抑制非小细胞肺癌中的 mTOR/E2F1/FANCD2 轴。
Br J Pharmacol. 2024 Apr;181(8):1221-1237. doi: 10.1111/bph.16281. Epub 2023 Dec 13.
5
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.蛋白酶体功能是DNA损伤反应和范可尼贫血途径激活所必需的。
Cancer Res. 2007 Aug 1;67(15):7395-405. doi: 10.1158/0008-5472.CAN-07-1015.
6
Promyelocytic Leukemia Proteins Regulate Fanconi Anemia Gene Expression.早幼粒细胞白血病蛋白调节范可尼贫血基因表达。
Int J Mol Sci. 2021 Jul 21;22(15):7782. doi: 10.3390/ijms22157782.
7
Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.范可尼贫血基因FANCD2和FANCF在白血病耐药分子机制中的作用。
Mol Med Rep. 2015 Jun;11(6):4605-10. doi: 10.3892/mmr.2015.3288. Epub 2015 Jan 30.
8
mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells.mTOR 通过 NF-κB 介导的 FANCD2 通路调控造血细胞中的 DNA 损伤反应。
Leukemia. 2013 Oct;27(10):2040-2046. doi: 10.1038/leu.2013.93. Epub 2013 Mar 29.
9
Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.范可尼贫血D2蛋白赋予对抗癌药物伊洛福芬的化学抗性。
Mol Cancer Ther. 2006 Dec;5(12):3153-61. doi: 10.1158/1535-7163.MCT-06-0427.
10
Ubiquitination Causes Fanconi Anemia-Linked ID Complex Ring Formation.泛素化导致范可尼贫血相关 ID 复合物环形成。
Cancer Discov. 2020 May;10(5):OF12. doi: 10.1158/2159-8290.CD-RW2020-043. Epub 2020 Mar 20.

引用本文的文献

1
Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine.使用mTORC2导向的RNAi纳米药物诱导三阴性乳腺癌细胞死亡和化疗敏感性
Cancer Res Commun. 2025 Mar 1;5(3):458-476. doi: 10.1158/2767-9764.CRC-24-0261.
2
Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.范可尼贫血途径抑制剂作为卵巢癌的潜在抗肿瘤药物
Explor Target Antitumor Ther. 2020;1(1):26-52. doi: 10.37349/etat.2020.00003. Epub 2020 Feb 29.
3
Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia.金雀花碱-CASIN 联合克服了人急性淋巴细胞白血病的化疗耐药性。
Nat Commun. 2021 Nov 26;12(1):6936. doi: 10.1038/s41467-021-27300-w.
4
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.抑制雷帕霉素靶蛋白（mTOR）可下调DNA修复蛋白的表达，并且与聚（ADP-核糖）聚合酶（PARP）抑制联合使用时，对BRCA2突变的乳腺癌具有高效性。
Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640.
5
mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.mTORC1和mTORC2协同调节乳腺癌细胞对DNA损伤和复制应激的转录及翻译重编程。
Mol Cell Biol. 2017 Feb 15;37(5). doi: 10.1128/MCB.00577-16. Print 2017 Mar 1.
6
Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer.人类癌症中范可尼贫血互补组D2蛋白（FANCD2）认识上的进展。
Cancer Cell Microenviron. 2015;2(4). doi: 10.14800/ccm.986. Epub 2015 Sep 7.
7
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.mTOR抑制剂抑制同源重组修复，并通过调控BRCA功能正常的三阴性乳腺癌中的SUV39H1与PARP抑制剂协同作用。
Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.
8
mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.mTORC1和DNA-PKcs作为对Chk1抑制敏感性的新型分子决定因素。
Mol Oncol. 2016 Jan;10(1):101-12. doi: 10.1016/j.molonc.2015.08.004. Epub 2015 Aug 25.
9
Glutaminolysis and autophagy in cancer.癌症中的谷氨酰胺分解与自噬
Autophagy. 2015;11(8):1198-208. doi: 10.1080/15548627.2015.1053680.
10
Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.癌症中的Mtor-范可尼贫血DNA损伤修复通路
J Oncobiomarkers. 2014;2(2). doi: 10.13188/2325-2340.1000008.

本文引用的文献

1
Molecular pathogenesis and clinical management of Fanconi anemia.范可尼贫血的分子发病机制与临床管理。
J Clin Invest. 2012 Nov;122(11):3799-806. doi: 10.1172/JCI58321. Epub 2012 Nov 1.
2
The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.PP242 是一种哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，可通过雷帕霉素复合物 1（TORC1）/真核翻译起始因子 4E（eIF-4E）/RAF 途径激活多发性骨髓瘤细胞中的细胞外信号调节激酶（ERK），这种激活是耐药的机制之一。
J Biol Chem. 2012 Jun 22;287(26):21796-805. doi: 10.1074/jbc.M111.304626. Epub 2012 May 3.
3
Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis.儿童白血病易感综合征：理解白血病发生的线索
Cancer Genet. 2011 May;204(5):227-44. doi: 10.1016/j.cancergen.2011.04.005.
4
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.降低 VEGF 产生、血管生成和血管再生有助于双重 mTORC1/mTORC2 抑制剂的抗肿瘤特性。
Cancer Res. 2011 Mar 1;71(5):1573-83. doi: 10.1158/0008-5472.CAN-10-3126.
5
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.活性位点 mTOR 抑制剂靶向抑制 mTORC1 和 mTORC2 对 T 细胞急性淋巴细胞白血病具有细胞毒性作用。
Leukemia. 2011 May;25(5):781-91. doi: 10.1038/leu.2011.20. Epub 2011 Feb 18.
6
The mTOR pathway: a new target in cancer therapy.mTOR 通路：癌症治疗的新靶点。
Curr Cancer Drug Targets. 2010 Aug;10(5):484-95. doi: 10.2174/156800910791517172.
7
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.哺乳动物雷帕霉素靶蛋白（mTOR）：指挥细胞信号交响乐。
J Biol Chem. 2010 May 7;285(19):14071-7. doi: 10.1074/jbc.R109.094003. Epub 2010 Mar 15.
8
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.雷帕霉素靶蛋白抑制剂西罗莫司与MEC化疗用于复发难治性急性髓系白血病的I期研究。
Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.
9
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.新型雷帕霉素哺乳动物靶点ATP竞争性选择性抑制剂的生化、细胞及体内活性
Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.
10
Defining the role of mTOR in cancer.确定mTOR在癌症中的作用。
Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008.